The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
The latest turmoil within Commissioner Marty Makary’s Food and Drug Administration, an alleged bribery scandal involving a high-level official, is no anomaly. The Sunday resignation of the Center for ...
An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...
The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...
A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts ...
Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.
Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...
Observers characterized the dismissals, policy reversals, and controversies at the FDA as a soap opera, total disarray, and potentially, unprincipled ...
Dr. George Tidmarsh, who joined the FDA in July, stepped down Sunday, The New York Times reported. His resignation came just ...
Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...
Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...
An update from Aurinia Pharmaceuticals ( ($AUPH) ) is now available. Aurinia Pharmaceuticals reported significant financial growth for the third ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback